[Clinical evaluation of anticancer therapy combined with p-aminobenzoic acid-N-xyloside].
Paraaminobenzoic acid-N-xyloside (K-247) is a new antitumor drug, which has no direct effect on immunologic status. Clinical trial of K-247 was performed in 8 patients with for advanced or recurred gastrointestinal cancer, who had short life expectancy. Oral administration of K-247, 600 to 900 mg/day, was carried out in combination with antitumor treatments using MMC, FT-207, 5-FU, PSK or irradiation. No toxic symptoms were observed in all patients. Of the 8 patients studied, one showed an encouraging response, while the remaining 7 patients were too far advanced to respond to these treatments.
D010129:4-Aminobenzoic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D062365:Aminobenzoates / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D062366:para-Aminobenzoates
D062365:Aminobenzoates; D000970:Antineoplastic Agents; D062366:para-Aminobenzoates; C035660:4-aminobenzoic acid-N-xyloside; D010129:4-Aminobenzoic Acid